Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Urogenital system
Patent
1997-03-24
1999-12-07
Witz, Jean C.
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Urogenital system
424643, 514560, 514494, A61K 3330, A61K 3548
Patent
active
059979089
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to compositions and pharmaceutical preparations that contain zinc prostate extract supplemented with zinc
BACKGROUND OF THE INVENTION
Diabetes is one of the most common metabolic disorders in humans. Indeed, nearly 1 million Americans are afflicted with juvenile-onset diabetes. This form of the disease is also known as insulin-dependent or Type I diabetes, and usually appears abruptly during childhood or young adulthood. Type II, or non-insulin-dependent diabetes is characterized by a less abrupt onset. Type II diabetes commonly occurs beyond the age of 40 or so. Both types of diabetes impair the body's ability to access blood glucose for use as an energy source. Chronically high levels of blood sugar gradually damage many tissues and organs of the body.
Substantial efforts have been directed toward understanding the causes and consequences of diabetes. A strong autoimmune component is now believed important in the etiology of type I diabetes (see Science 225:1381 (1984), and Immunology Today 5:230 (1984)). The metabolic consequences of experimentally induced diabetes have also been explored. For example, in Diabetes 31:426 (1982) Schneir et al. demonstrated that collagen, an important structural protein of skin, has a significantly decreased half-life in diabetic rats. It is well appreciated that both forms of diabetes impact the tissues of the body in a global fashion.
Despite the availability of insulin treatment, diabetes remains a serious disease that is responsible for many deaths and substantial morbidity worldwide. For example, the life-span of the average diabetic is shortened by as much as 50%. Although insulin treatment can assist in regulating blood sugar levels, the degree of this control is typically insufficient to prevent many of the sequelae from diabetes. The consequences from long term diabetes can include eye damage, often leading to blindness; circulatory problems; problems with wound healing; and other serious consequences. Improved treatments for diabetes are urgently required.
SUMMARY OF THE INVENTION
One aspect of the present invention is a composition of matter comprising a crystalline zinc chelated with extract of animal prostate tissue.
Another aspect of the present invention is a pharmaceutical composition that can be administered to a mammal. This pharmaceutical composition comprises crystalline zinc chelated with extract of animal prostate tissue and at least one pharmaceutically acceptable excipient. The composition can take the form of either a tablet or capsule. Each tablet or capsule of this composition preferably contains from about 20 to 150 milligrams of zinc.
A further aspect of the present invention is a method of treating diabetes. According to this method, a pharmaceutical composition that comprises a zinc chelated prostate extract is administered to a diabetic mammal in a quantity sufficient to reduce blood glucose concentration in that mammal.
Yet a further aspect of the present invention regards a pharmaceutical composition comprising an extract of animal prostate tissue for use in the treatment of diabetes. In a preferred embodiment, the pharmaceutical composition also comprises zinc.
Another aspect of the present invention is the use of an organic extract of animal prostate tissue in the preparation of a medicament for the treatment of diabetes.
Another aspect of the present invention is the use of prostate extract for the treatment of diabetes. The extract is preferably supplemented with zinc. Prostate extract can also be used in the preparation of a medicament for the treatment of diabetes. In one embodiment, the prostate tissue comprises a first group of molecules that are soluble in petroleum either or hexane. A subset of the molecules that are soluble in petroleum either or hexane is present in the prostate tissue. The prostate tissue also comprises a second group of molecules that are soluble in ethyl acetate or chloroform. The extract of animal prostate tissue can be obtained by a process compr
REFERENCES:
patent: 4302447 (1981-11-01), Horrobin
Langley et al., Genitourinary Medicine 63(4): 264-267 (Aug. 1987). Abstract.
M.K. Song, et al.; Journal of Nutrition; vol. 109, No. 12, Dec. 1979; pp. 2152-2158; "Evidence for an Important Role of Prostaglandins E.sub.2 and F.sub.2 in the Regulation of Zinc Transport in the Rat".
Moon K. Song, et al.; Comp.Biochem.Physiol., vol. 101A, No. 3, pp. 477-481, 1992; "Prostaglandin Interacts with Steriod Sex Hormones in the Regulation of Intestinal Zinc Transport".
M.K. Song, et al.; pp. E99-E-105; "Role of prostaglandin E.sub.2 in zinc absorption in the rat".
M.K.Song, et al.; Life Sciences, vol. 33, pp. 2399-2408; "A New Low-Molecular-Weight Calcium-Binding Ligand in Rat Small Intestine".
N.F. Adham, et al.; Nutrition and Metabolism; vol. 24: 281-290 (1980); "Effect of Calcium and Copper on Zinc Absorption in the Rat".
Moon K. Song, et al.; Comp.Biochem.Physiol.; vol. 85C, No. 2, pp. 283-289; 1986; "Relative Zinc-Binding Activities of Ligand in the Cytosol of Rat Small Intestine".
Moon K. Song; Comp.Biochem.Physiol.; vol. 87A, No. 2, pp. 223-230, 1987; "Low-Molecular-Weight Zinc-Binding Ligand: A Regulatory Modulator for Intestinal Zinc Transport".
Moon K. Song, et al.; Biological Trace Element Research; vol. 11, 1986; pp. 75-88; "Levels and Distribution of Zinc, Copper, Magnesium, and Calcium in Rats Fed Different Levels of Dietary Zinc".
M.K. Song., et al.; Biochemical Archives, vol. 1, pp. 75-83; "Metabolic Influences on Intestinal Zinc Uptake in Rats".
Moon K. Song, et al.; Biological Trace Element Research; vol. 6, 1984; "Metabolism of Zinc-Binding Ligands in Rat Small Intestine".
George Y. Luh, et al.; Comp.Biochem.Physiol.; vol. 91B, No. 3, pp. 569-576, 1988; "Characterization of the Low Mol. Wt Zinc-Binding Ligand From Rat Small Intestine by Comparison to the Organic Zinc-Binding Ligands".
S. Arver; Acta Physiol Scand 1982, 116:67-73; "Zinc and zinc ligands in human seminal plasma".
M. Schneir, et al.; Diabetes, vol. 31, May 1982; "Streptozotocin-induced Diabetic Rat Enhanced Catabolism of collagen Formed Both Before and During the Diabetic State".
M. Johnson, et al.; The Lancet I: 325-326, 1979; "Vascular Prostacyclin May be Reduced in Diabetes in Man".
K. Engelbart, et al.; Virchows Arch.Abt.B.Zellpath. 4, 294-302 (1970); "Uber das funktionelle Verhalten von Zink und Insulin in den B-Zellen des Rattenpankreas".
J.L. Marx; Science, vol. 225, pp. 1381-1383; Sep. 1984; "Diabetes--A Possible Autoimmune Disease".
L. Hurley, et al.; The Lance I: 1979; pp. 677-678; "Zinc Citrate, Human Milk and Acrodermatitis Enteropathica".
S. Katayama, et al.; Hypertension Program Unit, vol. 7, No. 4, Jul.-Aug. 1985; pp. 554-561; "Hypertension in Experimental Diabetes Mellitus Renin-Prostaglandin Interaction".
W.T. Johnson, et al.; J. Nutr. 115: 1217-1227, 1985; "Intestinal Absorption and Excretion of Zinc in Streptozotocin-Diabetic Rats as Affected by Dietary Zinc and Protein".
R.P. Robertson, et al.; Journal of Clinical Investigation, vol. 60, Sep. 1977; pp. 747-753; "A role for Prostaglandin E in Defective Insulin Secretion and Carbohydrate Intolerance in Diabetes Mellitus".
G.W. Evans, et al.; J.Nutr. 110:1076-1080, 1980; "Zinc Absorption in Rats Fed a Low-Protein Diet and a Low-Protein Diet Supplemented with Tryptophan or Picolinic Acid".
H.E. Harrison, et al.; Life Sciences, vol. 23, pp. 351-356; "Decreased Vascular Prostacyclin in Experimental Diabetes".
M.K. Chooi, et al.; Nutr.Metabol.20: 135-142 (1976); "Influence of Age and Sex on Plasma Zinc Levels in Normal and Diabetic Individuals".
Biochemical Medicine 23, pp. 231-235; 1980; Short Communications; "Altered Synthesis of Prostaglandins in Platelet and Aorta from Spontaneously Diabetic Wistar Rats".
R.J. Illman, et al.; Atherosclerosis, 59, 1986, pp. 313-321; "Time-Course of Changes in Plasma Lipids in Diabetic Rats Fed Diets High in Fish or Safflower Oils".
A. Reznikov, et al.; Endocrinologia Experimentalis, vol. 24, 1990; pp. 437-447; "Nonsteroid Antiandrogen
LandOfFree
Prostate extract supplemented with zinc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostate extract supplemented with zinc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate extract supplemented with zinc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-820883